Objective Despite significant advances in sanitation and medicine, infectious diseases still annually claim in excess of 15 million lives. Community acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Pneumonia is also the leading cause of death in children worldwide. It kills an estimated 1.6 million children under the age of five every year, about 25% of all pediatric deaths around the world – more than AIDS, malaria and tuberculosis combined . In the EU about 3.3 million cases are reported annually with hospitalization rates ranging from 20–50%, meaning that there are about 1 million hospital admissions for CAP per year in the EU . In addition, the growing resistance to antibiotic treatments (>10% in EU), makes pathogen identification and streamlining of antibiotic treatment even more important.AlphaSIP aims the development of a cost-effective solution for the rapid diagnostic of pneumonia.Infectious diseases represent the largest segment of the In-Vitro Molecular Diagnostics Market with nearly 50%. It is a big market that is growing fast: $ 5 B with a 14% CAGR. The Point-of-Care Molecular Diagnostics devices market for infectious diseases based on microfluidics has a size of approximately 900 M $ with an even higher growth rate . PneumoSIP product line is expected to become the main source of growth for the company in the next 5 years. The H2020 SME instrument phase I feasibility study has four main objectives:- To verify with final users (physicians and lab technicians) the features of the problem. - To validate and close the first specifications of the product with final users and customers. - To confirm with updated market studies the future Pn Fields of science medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesclinical medicinepneumologytuberculosismedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2014 Funding Scheme SME-1 - SME instrument phase 1 Coordinator LABORATORIOS ALPHA SAN IGNACIO PHARMA S.L. - ALPHASIP Net EU contribution € 50 000,00 Address CALLE CERVANTES 40 - 3P - PC 50006 ZARAGOZA Spain See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Noreste Aragón Zaragoza Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
